BG
ENZN

BlackRock Group’s ENZON PHARMACEUTICALS INC ENZN Stock Holding History

BlackRock Group’s Portfolio ENZN Stock Details ENZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-118,379
Closed -$199K – 2875
2013
Q3 		$199K Buy
+118,379
New +$219K ﹤0.01% 2484

Other funds holding ENZN

IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

BlackRock Group's ENZN Position: Q4 2013 in Review

BlackRock Group sold out of ENZON PHARMACEUTICALS INC (ENZN) in Q4 2013, closing a stake of 118,379 shares — an estimated $199K sold.

BlackRock Group first reported a position in ENZN in Q3 2013 and held it in 1 quarter. The position peaked at $199K in Q3 2013. 79 funds tracked by Wall St. Rank hold ENZN as of Q4 2013.

  • BlackRock Group reported no remaining ENZON PHARMACEUTICALS INC position as of Q4 2013 after selling out during the quarter.
  • BlackRock Group sold 118,379 ENZON PHARMACEUTICALS INC shares in Q4 2013, an estimated $199K.
  • BlackRock Group first reported a position in ENZON PHARMACEUTICALS INC in Q3 2013 and held it in 1 quarter.
  • BlackRock Group's ENZON PHARMACEUTICALS INC position peaked at $199K in Q3 2013.
  • 79 funds tracked by Wall St. Rank held ENZON PHARMACEUTICALS INC as of Q4 2013.

Based on BlackRock Group's 13F filing for Q4 2013, filed 12 Feb 2014.